Country: Jordan
Language: English
Source: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)
Dapagliflozin as propanediol monohydrate 5 mg
مستودع ادوية شاوي و رشيدات و مسنات - Shawi & Rushedat Drug Store
A10BX09
Dapagliflozin as propanediol monohydrate 5 mg
as propanediol monohydrate 5 mg
28
AstraZeneca Pharmaceuticals LP (امريكا)
21.68 :سعر الجمهور + الضريبة
1 FORXIGA TM (DAPAGLIFLOZIN) FILM-COATED TABLETS NAME OF THE MEDICINAL PRODUCT Forxiga 5 mg film-coated tablets Forxiga 10 mg film-coated tablets QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 mg tablet contains dapagliflozin propanediol monohydrate equivalent to 5 mg dapagliflozin. Each 10 mg tablet contains dapagliflozin propanediol monohydrate equivalent to 10 mg dapagliflozin. Excipient with known effect: Each 5 mg tablet contains 25 mg of lactose anhydrous. Each 10 mg tablet contains 50 mg of lactose anhydrous. For the full list of excipients, see List of excipients. PHARMACEUTICAL FORM Film-coated tablet (tablet). 5 mg tablet: Yellow, biconvex, 0.7 cm diameter round, film-coated tablets with “5” engraved on one side and “1427” engraved on the other side. 10 mg tablet: Yellow, biconvex, approximately 1.1 x 0.8 cm diagonally diamond-shaped, film-coated tablets with “10” engraved on one side and “1428” engraved on the other side. CLINICAL PARTICULARS THERAPEUTIC INDICATIONS Type 2 diabetes mellitus Forxiga is indicated in adults for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, - as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. 2 For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see Special warnings and precautions for use, Interaction with other medicinal products and other forms of interaction and Pharmacodynamic properties. Heart failure Forxiga is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. POSOLOGY AND METHOD OF ADMINISTRATION Posology Type 2 diabetes mellitus The recommended dose is 10 mg dapagliflozin once daily. When dapagliflozin is used in combination with insulin or an insulin secretagogue, such as a sulphonylurea, a lower dose of insulin or insulin secretagogue m Read the complete document